Dow Down0.08% Nasdaq Down0.25%

Neuralstem, Inc. (CUR)

3.39 Down 0.06(1.74%) 10:25AM EDT - Nasdaq Real Time Price
ProfileGet Profile for:
Neuralstem, Inc.
9700 Great Seneca Highway
Rockville, MD 20850
United States - Map
Phone: 301-366-4841

Index Membership:N/A
Full Time Employees:15

Business Summary 

Neuralstem, Inc., a biopharmaceutical company, focuses on the development and commercialization of treatments for central nervous system disease based on human neural stem cells and the use of small molecule compounds. The company’s stem cell technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its clinical program products include NSI–566, which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, and Phase I clinical trials for chronic spinal cord injury. The company’s clinical development products also comprise NSI–566 that is in Phase I/II clinical trials for motor deficits due to ischemic stroke in China; and NSI–189 that is in Phase Ib for the treatment of major depressive disorders. Neuralstem, Inc. was founded in 1996 and is headquartered in Rockville, Maryland.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Neuralstem, Inc.

Key Executives 
Dr. Karl Y. Johe Ph.D., 54
Co-Founder, Chairman and Chief Scientific Officer
Mr. I. Richard Garr J.D., 61
Co-Founder, Chief Exec. Officer, Pres, Chief Financial Officer, Principal Accounting Officer, Gen. Counsel and Director
Dr. Thomas Hazel Ph.D.,
Sr. VP of Research
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders